非布索坦治疗痛风患者疗效如何？

Febuxostat (febuxostat, feburic) is a drug developed by Teijin Pharmaceutical of Japan for the treatment of gout. Gout is a crystal-related arthropathy caused by the deposition of monosodium urate (MSU). It is directly related to hyperuricemia caused by purine metabolism disorder and/or reduced uric acid excretion. It specifically refers to acute characteristic arthritis and chronic tophi disease.

How effective is febuxostat in treating gout patients?

Febuxostat (febuxostat, feburic) is a newly developed drug, and at the same dose, febuxostat (febuxostat, feburic) has a stronger effect in reducing blood uric acid. Therefore, when it comes to the choice of gout acid-lowering drugs, many patients prefer febuxostat.

Clinical trials used a model-based meta-analysis method to analyze the effect of febuxostat (febuxostat, feburic) in the treatment of gout. Taking the response rate of patients' blood uric acid to less than 6 mg·dL-1 as the clinical endpoint, the efficacy of allopurinol and febuxostat was compared. A total of 22 clinical studies, 43 dose groups, and 6365 gout patients were included in this study. Through the establishment of the model, the response rate of allopurinol and febuxostat (febuxostat, feburic) changes with time and dose, as well as the blood uric acid level, and the impact of allopurinol non-responders on the response rate.

The results showed that the average maximum response rate with allopurinol treatment was 50.8%. Febuxostat (febuxostat, feburic) has good efficacy, and its efficacy reaches stability quickly after administration. The ED50 value of febuxostat is 34.3 mg through model fitting. There is a negative correlation between the patient's basal serum uric acid level and the allopurinol response rate, while the ED50 of febuxostat increases with the increase in the patient's basal serum uric acid level. For patients in whom allopurinol alone is not effective, the average maximum response rate is approximately 1/2 of that of allopurinol responders.